Thin basement membrane disease pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Thin basement membrane disease}} {{CMG}} ==Overview== ==Pathophysiology== The molecular basis for thin basement membrane disease has yet to be elucidated fully; ...")
 
No edit summary
Line 6: Line 6:


==Pathophysiology==
==Pathophysiology==
The molecular basis for thin basement membrane disease has yet to be elucidated fully; however, defects in [[type IV collagen]] have been reported in some families.<ref name="pmid12969134">{{cite journal |author=Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY |title=Thin basement membrane nephropathy |journal=Kidney Int. |volume=64 |issue=4 |pages=1169–78 |year=2003 |month=October |pmid=12969134 |doi=10.1046/j.1523-1755.2003.00234.x}}</ref><ref name="pmid17726307">{{cite journal |author=Hou P, Chen Y, Ding J, Li G, Zhang H |title=A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy |journal=Am. J. Nephrol. |volume=27 |issue=5 |pages=538–44 |year=2007 |pmid=17726307 |doi=10.1159/000107666 |url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000107666}}</ref>
'''Physiology'''
Glomerular Basement membrane is consists of laminin, Type 4 collagen, heparan sulfate proteoglycan and nidogen. Type 4 collagen is generally composed of Gly-X-Y amino acids rich in six alpha chains (alpha 1-6) that gives type 4 collagen a trimeric shape. The nascent GBM is made up of alpha 1 and 2 initially, then alpha 3-4 trimers are secreted after glomerular capillaries formation which becomes the major component of type 4 collagen and giving the GBM its stability.<ref name="pmid22410250">{{cite journal |vauthors=Miner JH |title=The glomerular basement membrane |journal=Exp. Cell Res. |volume=318 |issue=9 |pages=973–8 |date=May 2012 |pmid=22410250 |pmc=3334451 |doi=10.1016/j.yexcr.2012.02.031 |url=}}</ref>


Some individuals with TBMD are thought to be carriers for genes that cause [[Alport syndrome]].<ref name="pmid11473630">{{cite journal |author=Buzza M, Wang YY, Dagher H, ''et al.'' |title=COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome |journal=Kidney Int. |volume=60 |issue=2 |pages=480–3 |year=2001 |month=August |pmid=11473630 |doi=10.1046/j.1523-1755.2001.060002480.x}}</ref>
'''Pathology'''
Heterozygous mutation in COL4A3 and COL4A4 is responsible for causing autosomal dominant pattern of 40-50% of Thin basement membrane disease. <ref name="pmid22410250">{{cite journal |vauthors=Miner JH |title=The glomerular basement membrane |journal=Exp. Cell Res. |volume=318 |issue=9 |pages=973–8 |date=May 2012 |pmid=22410250 |pmc=3334451 |doi=10.1016/j.yexcr.2012.02.031 |url=}}</ref> And heterozygous mutation in COL4A5 gene in X-chromosome may cause Thin basement mamebrane disease in female. 
 
'''Genetics'''
'''Associated condition'''
'''Gross pathology'''
'''Microscopic pathology'''


==References==
==References==

Revision as of 20:48, 3 October 2020

Thin basement membrane disease Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thin basement membrane disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thin basement membrane disease pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thin basement membrane disease pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thin basement membrane disease pathophysiology

CDC on Thin basement membrane disease pathophysiology

Thin basement membrane disease pathophysiology in the news

Blogs on Thin basement membrane disease pathophysiology

Directions to Hospitals Treating Thin basement membrane disease

Risk calculators and risk factors for Thin basement membrane disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Physiology Glomerular Basement membrane is consists of laminin, Type 4 collagen, heparan sulfate proteoglycan and nidogen. Type 4 collagen is generally composed of Gly-X-Y amino acids rich in six alpha chains (alpha 1-6) that gives type 4 collagen a trimeric shape. The nascent GBM is made up of alpha 1 and 2 initially, then alpha 3-4 trimers are secreted after glomerular capillaries formation which becomes the major component of type 4 collagen and giving the GBM its stability.[1]

Pathology Heterozygous mutation in COL4A3 and COL4A4 is responsible for causing autosomal dominant pattern of 40-50% of Thin basement membrane disease. [1] And heterozygous mutation in COL4A5 gene in X-chromosome may cause Thin basement mamebrane disease in female.

Genetics Associated condition Gross pathology Microscopic pathology

References

  1. 1.0 1.1 Miner JH (May 2012). "The glomerular basement membrane". Exp. Cell Res. 318 (9): 973–8. doi:10.1016/j.yexcr.2012.02.031. PMC 3334451. PMID 22410250.

Template:WH Template:WS